Health Care & Life Sciences » Pharmaceuticals | Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.
Stock Exchange Other OTC
EPS
$0.03
Market Cap
$7.74 M
Shares Outstanding
54 M
Public Float
-
Aequus Pharmaceuticals Inc.
Stock Exchange Toronto Ventures Stock Exchange
EPS
CAD0.04
Market Cap
CAD9.91 M
Shares Outstanding
80.44 M
Public Float
64.56 M

Profile

Address
200 Granville Street
Vancouver British Columbia V6C 1S4
Canada
Employees -
Website http://www.aequuspharma.ca
Updated 07/08/2019
Aequus Pharmaceuticals, Inc. focuses on the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.

Financials

View All
Created with Highcharts 5.0.14Aequus Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values CAD Thousands.5 0115 0114 8124 8123 8823 8822 8032 803201520162017201801k2k3k4k5k6k
Created with Highcharts 5.0.14Aequus Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values CAD Thousands.007017011 1391 1391 4101 41020152016201720180250500750100012501500

Douglas Glen Janzen
Chairman, President & Chief Executive Officer
Anne Michelle Stevens
Chief Operating Officer, Secretary & Director